-
Views
-
Cite
Cite
Joyce C. West, Steven C. Marcus, Joshua Wilk, Lisa M. Countis, Darrel A. Regier, Mark Olfson, Use of Depot Antipsychotic Medications for Medication Nonadherence in Schizophrenia, Schizophrenia Bulletin, Volume 34, Issue 5, September 2008, Pages 995–1001, https://doi.org/10.1093/schbul/sbm137
- Share Icon Share
Abstract
Objectives: To describe factors associated with initiation of depot antipsychotic medications in psychiatric outpatients with schizophrenia and recent medication nonadherence. Methods: A national sample of psychiatrists reported on adult outpatients with schizophrenia who were nonadherent with oral antipsychotic medications in the last year. Results: In total, 17.6% of psychiatrists initiated depot antipsychotic injections. Initiation was significantly and positively associated with public insurance, prior inpatient admission, proportion of time nonadherent, average or above average intellectual functioning, and living in a mental health residence. Use was inversely associated with using second-generation antipsychotics and other oral psychotropic medications prior to medication nonadherence. Psychiatrists who were male, nonwhite, and more optimistic about managing nonadherence were more likely to initiate depot injections. Conclusions: Initiation of depot injections is a joint function of patient, physician, treatment, and setting factors. Use of long-acting preparations in this population is uncommon despite clinical recommendations urging their use.